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Abstract
Objectives: This study aimed to determine the impact of a standardized pathological protocol on
resection margin status after pancreaticoduodenectomy (PD) for ductal adenocarcinoma.
Methods: A total of 150 patients operated during 2008–2010 were included in a prospective multicentre
study using a ‘quality protocol’. Multicolour inking by the surgeon identified three resection margins: the
portal vein–superior mesenteric vein margin (PV-SMVm) or mesenterico–portal vein groove; the superior
mesenteric artery margin (SMAm), and the posterior margin. Resection margins were stratified by 0.5-mm
increments (range: 0–2.0 mm). Pancreatic neck, bile duct and intestinal margins were also analysed.
Correlations between histopathological factors and survival in the 0-mm resection margin group were
analysed.
Results: Thirty-six patients (24%) had a PV-SMV resection (PV-SMVR). An analysis of resections cat-
egorized according to margin distances of 0 mm, <1.0 mm, <1.5 mm and <2.0 mm confirmed R1 resec-
tions in 35 (23%), 91 (61%), 94 (63%) and 107 (71%) patients, respectively. The most frequently invaded
resection margin was the PV-SMVm (35% of all patients) and PV-SMVR was the only factor correlated
with a higher risk for at least one 0-mm positive resection margin on multivariate analysis (P < 0.001).
Two-year progression-free survival (PFS) and median PFS time in patients with R0 and R1 resections (at
0 mm), respectively, were 42.0% and 26.5%, and 19.5 months and 10.5 months, respectively (P = 0.02).
A positive PV-SMVm and SMAm had significant impact on PFS, whereas a positive posterior margin had
no impact.
Conclusions: Pancreaticoduodenectomy requiring PV-SMVR was associated with a higher risk for R1
resection. The standardization of histopathological analysis has a clinically relevant impact on PFS data.
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Introduction
With more than 278 000 new diagnoses each year worldwide,
pancreatic ductal adenocarcinoma (PDAC) accounts for 10%of all
digestive system cancers.1 Some 266 000 of these newly diagnosed
patients will die.1,2 The annual incidence rate approximates the
mortality rate,which exceeds annual prevalence.Curative resection
with negative resection margins (R0 resection) represents the only
chance of cure, but the rate of such resections is remarkably low
as a result of the lack of early specific biological markers, non-
specific symptoms at presentation, delayed diagnosis and early
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metastasis.2–4 The prognosis remains extremely poor, with 5-year
survival rates of <5% in the EU andUSA.2–4 As a generally accepted
oncological principle after the resection of a solid tumour, micro-
scopic resection margin involvement (R1) has been reported as an
independent predictor of poor longterm survival following pan-
creaticoduodenectomy (PD) for PDAC in several studies,5–21 but
not in others.22,23 Underreporting of microscopic margin involve-
ment may cause some discrepancy between margin status and
clinical outcome,andhence the clinical significance of R1 resection
remains unclear.24,25 There has recently been increased interest in
resectionmargin involvement in PDAC, as well as in its prognostic
and therapeutic implications. The standardization of pathological
examination increased the rate of R1 resections after PD from 20%
to 50%10,12 and to >70% when an intensified histopathological
workup was applied.20,26–34
Adjuvant chemotherapy after PD for PDAC is presently the
standard of care in the EU.6,35 Significant progress has been made
in preoperative imaging, and major improvements have been
achieved surgically in terms of postoperative morbidity and mor-
tality.36 However, assessment of the quality of histopathological
reporting on margin status, as well as the quality of the resection,
should represent a crucial step towards patient stratification. The
results of randomized multicentre trials evaluating adjuvant
therapy for PDAC should be interpreted according to those set-
tings.37 In the present study, a surgical quality protocol and a
standardized pathological workup were applied prospectively to
150 consecutive pancreatic head resections for PDAC performed
in French tertiary referral centres.
Materials and methods
Patient series
A prospective French multicentre study approved by the National
Cancer Institute (INCA) commenced in August 2008 (ClinicalTri-
als.gov identifier: NCT00918853). Enrolment closed in May 2010.
The collection of data for primary outcome measures was com-
pleted in May 2012. A total of 214 patients with periampullary
tumours provided informed consent to their inclusion in the
study before laparotomy, and 150 patients (70%) with true mac-
roscopically margin-free PDAC underwent PD and entered the
present study. Exclusion criteria applied after surgery included
findings of macroscopic residual tumour in the operative field (R2
resection), non-adherence to the surgical protocol, non-ductal
adenocarcinoma, and margin analysis performed without using
the predefined criteria. Sixty-four (30%) patients with distal bile
duct cancers, ampullary tumours, neuroendocrine tumours, non-
invasive intraductal papillary mucinous neoplasm (IPMN) and
periampullary tumours of various aetiologies were excluded after
histopathological review. Any doubtful diagnosis led to the exclu-
sion of that patient from the study.
Standardized PD by ‘quality protocol’
Circumferential dissection of the portal vein–superior mesenteric
vein (PV-SMV) axis and dissection of the right hemi-
circumference of the superior mesenteric artery (SMA) to the
right of the coeliac trunk were required to obtain a good medial
clearance (Fig. 1). The dissection of the SMA removed all soft
tissue to the right of the adventitia, which corresponded to the
SMA margin (SMAm) on the specimen.22,38–40 This technique
obviated the need for intraoperative frozen-section analysis of the
SMAm. A standard lymphadenectomy plus resection of lymph
nodes to the right of the coeliac trunk, hepatic artery and hepa-
toduodenal ligament were carried out in all patients.41 The pan-
creatic neck transection margin and the common bile/hepatic
duct transection margins were evaluated using frozen-section
analysis and, if results were positive, additional tissue was resected
to achieve negative margins at these two sites. En bloc resection of
the SMV, PV or PV-SMV confluence was performed in 36 patients
(PV-SMVR: 24%); PV-SMVR was planned in half of these
patients and performed in the other half in response to intraop-
erative suspicion of venous wall invasion. Four patients were sub-
jected to combined arterial resection as a result of the abutment or
encasement of a short segment of the hepatic artery. Three
patients underwent en bloc right colectomy for invasion of the
mesocolon.
The surgeon clearly identified the margins in the operative
room with multicolour coded inking of: (i) the mesenterico–
portal vein groove or PV-SMV margin (PV-SMVm); (ii) the SMA
margin (SMAm), and (iii) the posterior margin (Fig. 2). In cases
of PV-SMVR, the venous segment was clearly identified on the
specimen (Fig. 3). The anterior surface was not considered as a
transection margin and was not inked.
Standardization of the protocol for
pathological examination
Serial slicing of the entire pancreatic head specimen was per-
formed in a single axial plane (i.e. perpendicular to the longitu-
dinal axis of the duodenum) according to the guidelines of the
Royal College of Pathologists and the Leeds Pathology Proto-
col.26,27,29,40,42 Thus, large slices were obtained (median number:
12), allowing a precise study of each inked margin in increments
of 0.5 mm from 0 mm to 2.0 mm. Margin involvement (R1) was
defined for the 0-mm margin if tumour cells were present at the
inked margin; R1 was also defined for each margin width if
tumour cells were present within themargin, independently of the
mode of tumour spread. The ‘vascular’ margin was defined as the
PV-SMVm plus SMAm inked margins. Patients undergoing
PV-SMVR for local invasion were considered to have a positive
PV-SMVm if tumour was present at the resection margin, not
simply intraluminally. The resection was considered as curative
(R0) if no tumour cells were identified at any of the resection
margins (including bile duct and pancreatic neck non-inked
transection margins), again for each margin width (see Appen-
dix). The pathological protocol also included the maximal trans-
verse diameter of the tumour, the tumour–node–metastasis
(TNM) classification, the grade of differentiation, the presence or
absence of perineural, lymphatic and/or vascular spread, and the
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number of lymph nodes retrieved from the specimen, enabling
the calculation of the lymph node ratio (LNR). The presence and
grading of pre-neoplastic lesions were also recorded. In
PV-SMVR, the length of the resection was recorded and the
margins of the vessel segment were examined; if the vein was
invaded, the depth of invasion was specified (invasion of adven-
titia, media or intima). Pathological data for PD specimens with
PV-SMVR were compared with data for PD specimens without
PV-SMVR.
Power and sample size considerations
The primary objective of this prospective multicentre study was to
confirm the negative impact on longterm clinical outcome of
resection margin involvement (R1 or R0) in patients with PDAC
who underwent PD according to a standardized protocol. As
defined in the protocol, the main evaluation criterion was overall
survival (OS): a minimum of 87 deaths were required to reach
90% power using a two-sided 0.05-level log-rank test to detect a
significant difference in hazard ratio (HR) between R1 and R0
status, assuming a true HR difference (HR = 2.0). In response to
an unexpectedly low 2-year death rate, the initial sample size (n =
156) was increased. A total of 214 patients were recruited prior to
laparotomy, of whom 150 with proven macroscopically margin-
free PDAC entered this prospective 2-year follow-up study period.
The first patient was accrued in August 2008 and the last in May
2010.
Follow-up
According to the protocol, patients were scheduled to be followed
for a 2-year fixed period. Postoperative mortality was defined as
in-hospital mortality or mortality within 30 days of discharge
(five patients). Patients were followed every 4 months after dis-
charge and evaluated using computed tomography (CT) and car-
bohydrate antigen 19-9 (CA 19-9) levels, or reviewed for any
abnormal symptom. If an isolated elevation of CA 19-9 occurred
[i.e. without documented CT or positron emission tomography
(PET)-CT recurrence], the patient was followed every 2 months.
Figure 1 Standardized pancreaticoduodenectomy. Operative view showing: (a) the dissection of the right hemi-circumference of the superior
mesenteric artery (SMA) with elective division of the pancreaticoduodenal arteries (red arrows); (b) clearance of the medial margin (green
arrows) with no residual soft tissue to the right of the SMA. Note the circumferential dissection of the mesenterico–portal venous axis. HA,
hepatic artery; SV, splenic vein; GV, gastric vein; GDA, stump of the gastroduodenal artery; PT, pancreatic transection; IVC, inferior vena
cava
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Recurrences were defined as locoregional or metastatic (including
peritoneal carcinomatosis) events or both.
As of May 2012, when data collection was completed, all demo-
graphic clinical and histological characteristics were monitored
and centrally reviewed; however, longterm clinical outcome data
collection remains ongoing or under resolution. According to
these preliminary longterm data, 66 patients died and 71 (47%)
demonstrated disease progression. To preserve the power of this
prospective study, the time to progression or death was defined as
the primary evaluation criterion in a revised statistical analysis
plan issued in blind conditions.
Statistical analysis
Descriptive statistics were used to summarize the clinical and
histological characteristics of the full cohort of patients who
entered the prospective follow-up study period (n = 150). Two
groups of patients were first considered: patients who underwent
standard PD (n = 114), and patients who underwent PD with
PV-SMVR (n = 36). Differences between the groups in patient
characteristics were assessed using the chi-squared test for cat-
egorical variables and the Wilcoxon rank sum test for continuous
variables. The main objective of this study was to evaluate micro-
scopic involvement on at least one of the inked resection margins
and to identify factors correlated with resection margin involve-
ment. A selection of factors that may influence microscopic
involvement were established prior to data analysis and then cat-
egorized using predefined cut-offs [age, sex, body mass index
(BMI), Karnowsky index, conventional pathological factors,
venous resection,preoperative treatments].Factors correlatedwith
positive margins at each increment were identified using the non-
parametric Fisher’s (exact) chi-squared test.All factors found to be
significant at the 0.05 level or to be of borderline significance at the
0.15 level in univariate analysis were entered into a multivariate
logistic regressionmodel to identify independent factors correlated
with microscopic involvement at each margin increment. Similar
univariate and multivariate analyses were carried out for each
category of margin involvement defined according to the presence
of tumour cells at the inkedmargin andwithin resectionmargins in
0.5-mm increments. Preliminary longterm clinical outcome data
were used to measure the prognostic impact of microscopic
involvement on at least one inkedmargin.Median survival,OS and
progression-free survival (PFS) were calculated for the 0-mm
margin. Thus, the following results are preliminary data because
the positive margin is defined by the presence of tumour cells at
0 mm.38,39 Patients alive without disease progression and patients
alive at the end of follow-up were considered as censored on the
right at the date of last contact. Time to progression or death (PFS)
and time to death (OS) defined from the date of PD to the date of
the event analysed were summarized using the Kaplan–Meier
method and comparisons were made using the log-rank test. All
statistical analyses were carried out using sas Version 9.3 (SAS
Institute, Inc.,Cary,NC,USA). Statistical significancewas accepted
at the 5% level with no adjustment for multiple testing.
Results
Demographics are shown in Table 1. The study group included 95
men and 55 women, with a median age of 63 years (range: 41–84
years). Twenty-two (15%) patients had IPMN with invasive
cancer. Twenty-nine (19%) patients received neoadjuvant treat-
ment (FOLFIRINOX: n = 12; gemcitabine or 5-fluorouracil and
platinum-based chemoradiation: n = 17), mostly for suspicion of
involvement of more than half of the circumference of the venous
axis on the portal phase of the preoperative CT. Nine of the 36
PV-SMVRs and all four arterial resections were performed after
neoadjuvant treatment.
Clinicopathological data for the entire cohort are reported in
Table 1. A total of 78% of the tumours were classified as T3
tumours (T1: 8%; T2: 9%; T4: 5%).More than half of the tumours
were moderately differentiated (grade 1: 30%; grade 2: 52%; grade
3: 19%). Significantly more poor prognostic factors were observed
in the PD with PV-SMVR group (Table 1).
Margin status
The mean and median distances separating tumour cells from
each inked margin are reported in Table 2. Microscopic involve-
ment was present on at least one of the inked margins in 35
patients (23%) at the 0-mm margin and in 91 (61%), 94 (63%)
and 107 (71%) patients at the 1.0-mm, 1.5-mm and 2.0-mm
margins, respectively (Table 1). The number of patients in whom
two or three margins were involved increased from 14 for the
Figure 2 Cross-section of the pancreatic head showing the inked
margins: the mesenterico–portal vein groove (medial circumferential
resection margin) in blue, the superior mesenteric artery (SMA)
margin (uncinate margin) in red and the posterior margin in yellow. D,
duodenum; DJF, duodenojejunal flexure; CBD, common bile duct;
AO, aorta; IVC, inferior vena cava; SMV, superior mesenteric vein
HPB 23
HPB 2014, 16, 20–33 © 2013 International Hepato-Pancreato-Biliary Association
0-mm margin (14/35, 40%) to 40 (40/91, 44%), 43 (43/94, 46%)
and 66 (66/107, 62%) for the 1.0-mm, 1.5-mm and 2.0-mm
margins, respectively (Table 3).
The rates of positive inked margins within each increment are
reported in Table 1. More invaded margins were observed in the
PV-SMVR group (Table 1). The most frequently invaded margin
was the PV-SMVm.
Invasion of the ‘vascular’ margin (PV-SMVm plus SMAm) was
present in 23% of specimens at the 0-mm margin and in close to
50% at the 1.0-mm and 1.5-mmmargins. Despite the intraopera-
tive frozen-section analysis, 1% (n = 2) of bile duct transections
and 5% (n = 8) of pancreatic neck transections were found to be
invaded on final examination.
In summary, if R1 resection is defined by a positive margin of
0 mm,38,39,43,44 23% of the present patients achieved R1 resection.
If R1 resection is defined by the presence of tumour cells within
1.0 mm40,42,45 or 1.5 mm,46 61% and 63%, of the present patients
achieved R1 resection. Bile duct and pancreatic neck transection
invasion resulted in an additional 7% of R1 resections for any
definition of R1 on the inked margins. Thus, the rate of R1
resections was 30% when R1 was defined according to the 0-mm
rule and 68% when R1 was defined according to the 1.00-mm
rule (ratio: 2.3).
Univariate and multivariate analyses of factors associated with
the risk for a positive inkedmargin at each increment are shown in
Tables 4 and 5.
Figure 3 Pancreaticoduodenectomy with venous resection. (a) Operative view of venous confluence reconstruction. (b) A simple trick to
identify the vein for the pathologist: a small drain is gently inserted into the venous lumen; the vein is inked to show the portal vein groove
(PV-SMVm). (c) Photographic reconstruction of the venous axis with a medial and posterior view of the specimen. RHA, right hepatic artery;
PV, portal vein; SI, liver segment I; GV, gastric vein; ICV, ileo-colic vein; JV, jejunal vein; SV, splenic vein; IMV, inferior mesenteric vein;
SMAm, superior mesenteric artery margin; Pm, posterior margin
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Clinical impact of resection margin status
Themedian follow-upwas 24.1months (range: 23.7-24.8months).
Six (4%) patients were lost to follow-up (median follow-up: 7.5
months; range: 1.4-16.1 months). During the follow-up period, 66
(44%) patients died and disease progression was observed in 71
(47%) patients; five (3%) patients died from perioperative causes.A
total of 54 (37%) patients developed one or more metastases, with
(n = 15, 10%) or without (n = 39, 27%) local recurrence. In 16
(11%) patients, local recurrence was isolated. Eight patients with
isolated local recurrence had R0 resections.
Table 1 Comparison of clinicopathological data for the entire cohort and in the standard pancreaticoduodenectomy (PD) group and the PD
with portal vein–superior mesenteric vein resection (PV-SMVR) group
All patients
(n = 150)
Standard PD
(n = 114)
PD with
PV-SMVR
(n = 36)
P-value
(c2 or Wilcoxon
test)
Age, years, median (range) 63 (41–84) 64 (41–84) 62 (41–78) 0.135
Male, n (%) 95 (63%) 72 (63%) 23 (64%) 0.909
Female, n (%) 55 (37%) 42 (37%) 13 (36%)
pT3, n (%) 111 (74%) 80 (70%) 31 (86%) 0.057
pN1, n (%) 108 (72%) 78 (68%) 30 (83%) 0.417
Grade 3, n (%) 24 (19%) 14 (15%) 10 (28%) 0.037
Tumour size, cm, median (range) 3.5 (0.21–12) 3 (0.21–9) 4 (1.5–12) <0.001
LN retrieved, n, median (range) 23 (3–80) 19 (3–55) 37 (7–80) <0.001
Disease-positive LN, n, median (range) 3 (0–50) 2 (0–16) 3 (0–50) 0.211
LNR, median (range) 0.11 (0–0.75)
42 (29%)
0.12 (0–0.75)
34 (32%)
0.08 (0–0.72)
8 (22%)
0.552
0.785
Neoadjuvant treatment, n (%) 29 (19%) 20 (18%) 9 (25%) 0.323
Positive margin status for the 0-mm margin
At least one positive margin, n (%) 35 (23%) 17 (15%) 18 (50%) <0.001
Pm, n (%) 11 (7%) 4 (4%) 7 (19%) 0.009
PV-SMVm, n (%) 27 (18%) 12 (11%) 15 (42%) <.001
SMAm, n (%) 15 (10%) 6 (5%) 9 (25%) <.001
Vascular margina, n (%) 34 (23%) 16 (14%) 18 (50%) <.001
Positive margin status for the 1.0-mm margin
At least one positive margin, n (%) 91 (61%) 63 (55%) 28 (78%) 0.016
Pm, n (%) 52 (37%) 35 (31%) 17 (47%) 0.069
PV-SMVm, n (%) 61 (41%) 39 (34%) 22 (61%) 0.004
SMAm, n (%) 37 (25%) 24 (21%) 13 (36%) 0.067
Vascular margina, n (%) 73 (49%) 48 (42%) 25 (69%) 0.004
Positive margin status for the 1.5-mm margin
At least one positive margin, n (%) 94 (63%) 66 (58%) 28 (89%) 0.031
Pm, n (%) 40 (27%) 21 (18%) 19 (53%) 0.131
PV-SMVm, n (%) 62 (41%) 40 (35%) 22 (61%) 0.006
SMAm, n (%) 40 (27%) 26 (23%) 14 (39%) 0.057
Vascular margina, n (%) 74 (49%) 49 (43%) 25 (69%) 0.006
Positive margin status for the 2.0-mm margin
At least one positive margin, n (%) 107 (71%) 76 (67%) 31 (86%) 0.025
Pm, n (%) 54 (36%) 34 (30%) 20 (56%) 0.187
PV-SMVm, n (% 78 (52%) 54 (47%) 24 (67%) 0.043
SMAm, n (%) 54 (36%) 36 (32%) 18 (50%) 0.045
Vascular margina, n (%) 87 (58%) 59 (52%) 28 (78%) 0.006
aVascular margin: SMAm + PV-SMVm.
LN, lymph node; LNR, lymph node ratio; Pm, posterior margin; PV-SMVm, portal vein–superior mesenteric vein margin; SMAm, superior mesenteric
artery margin (uncinate margin).
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Median OS in the 150 patients was 20 months [95% confidence
interval (CI) 16.4–22.6]. Patients with at least one positive inked
margin had median survival of 17.7 months (11.7–36.4), whereas
patients with R0 resections had amedian survival of 32.9months [P
= 0.10; 95% CI 22.7 – not reached (NR)]. Two-year OS rates in
patients with R0 and R1 resections were, respectively, 59.3% (95%
CI 48–69) and 44.6% (95% CI 27–61) (P = 0.106; HR = 0.64, 95%
CI 0.37–1.11) (Fig. 4). Median and 2-year rates of PFS by margin
status are shown in Fig. 5 and Table 6. The relationship between
margin status at each increment and survival is yet to be determined.
Discussion
This study is the first prospective multicentre study of resection
margins in PDAC specimens to use a surgical quality protocol and
a standardized pathological workup. Despite recommendations
published since 1996,47–51 there is no consensus today on PD speci-
men handling and the assessment of resection margins. There is
also a lack of consensus regarding the definition of microscopic
margin involvement. However, this topic has recently attracted
increasing interest.20,21,26–34,46
There is marked heterogeneity in published rates of R1 resec-
tion. Most series have reported rates well below 20–40%, by con-
trast with those that report rates of >70% in series using a
standardized protocol for the pathological examination of PD
specimens.24,28–34 These discrepancies are mainly caused by differ-
ences in pathological assessment rather than in surgical procedure
and patient selection,26–28,30–34 although outcomes in low-volume
centres negatively affect the rate of positive resection margins.52
The Leeds24 and Heidelberg28 groups were the first to demonstrate
that the standardization of histopathological study resulted in a
significant increase in R1 resection rates, without requiring any
change in surgical technique (respectively, from 53% to 85%24 and
14% to 76%28). Thus, a high rate of R1 resection in PDAC is clearly
a marker of high-quality pathology and depends firstly on the
number of peri-pancreatic soft tissue resection margins exam-
ined, secondly on the number of blocks analysed,27,42 and thirdly
on the minimum clearance in millimetres used to define micro-
scopic margin involvement (R1).
In a study published recently by Campbell et al., tumour
involvement within 1.0 mm of, but not directly reaching, one or
more resection margins represented 45% of the 79% of resection
margins identified as positive.30 In the most recent series, com-
parisons of R1 rates achieved using the Union for International
Cancer Control (UICC) criteria (R1: 0 mm definition), which are
commonly used in North America,22,38,39,43,44 and those achieved
using the UK Royal College of Pathologists (RCPath) criteria (R1:
1.0 mm definition)42 show ratios ranging from 1.3 to 1.8.28,30–32,34
The ratio was 2.3 in the present study. Katz et al. reported a ratio
of 5.5 (4–22%) in a study in which only the SMAm was assessed
and in which 76% of patients had received preoperative radioche-
motherapy; this study also showed that preoperative CT overesti-
mated the SMAm in 73% of patients.53 Hartwig et al. reported a
maximum ratio of 8.4 in a study comparing the 0 mm definition
to the revised ‘R1 = 1.0 mm’ definition (4.8–40.5%).15
The confusing terminology used to define resection margins,
which is sometimes ambiguous,makes it difficult to compare rates
of microscopic invasion for each of the margins27 (see Appendix).
The assessment of resection margins is often limited to those of
the pancreatic neck and bile duct transections and the SMAm or
medial margin.12,22,37,47–49 However, the medial circumferential
resection margin (CRM),26 which faces the superior mesenteric
vessels, and the posterior soft tissue margins were the most fre-
quently involved.8,12,18,20–22,26–34 In the present study, assessments of
the SMAm and SMVm were clearly distinct,8,40 and these medial
resection margins, which represent true transection resection
Table 2 Mean and median clearances observed for each inked margin. In some patients the margin status was specified as positive or
negative for each of the increments, but the precise distance between the margin and the tumor cells was not clearly specified
Inked margins (number of patients with a
specified distance in mm)
Mean clearance
(mm  SD)
Median clearance
(mm; range)
Pm (129/150) 5.6 ( 7) 3.00 [0.10–35.00]
PVSMVm (115/150) 6.8 ( 6.9) 3.00 [0.10–20.00]
SMAm (123/150) 9.0 ( 9.6) 5.00 [0.20–30.00]
«Vascular» margin (PVSMVm + SMAm; 106/150) 5.8 ( 6.6) 2.25 [0.10–20.00]
Table 3 R1 resection rate for each margin increment (0–2.0 mm) and proportions of patients with at least one, two or three positive margins,
respectively. R1 resection rates were comparable across the 1.0-mm and 1.5-mm margin widths
Margin widths,
mm
R1 resections,
n/n (%)
One positive margin,
n/n (%)
Two positive margins,
n/n (%)
Three positive margins,
n/n (%)
0 35/150 (23%) 21/35 (60%) 10/35 (29%) 4/35 (11%)
1.0 91/150 (61%) 51/91 (56%) 21/91 (23%) 19/91 (21%)
1.5 94/150 (63%) 51/94 (54%) 23/94 (24%) 20/94 (21%)
2.0 107/150 (71%) 41/107 (38%) 38/107 (36%) 28/107 (26%)
26 HPB
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Table 4 Univariate analysis of factors associated with at least one positive margin for each of the margins at each width from 0 mm to
2.0 mm. Three non-pathological factors were significantly associated with a positive margin: male sex; portal vein–superior mesenteric vein
resection (PV-SMVR), and neoadjuvant treatment. Values in bold refer to factors that reached significance at a P-value of <0.05; values in
italics refer to factors that did not reach significance at a P-value of <0.05, but tended towards significance at a P-value of <0.10
Margin widths, mm
0 0.5 1.0 1.5 2.0
Margins Variables P-value
Odds ratio (95% confidence interval)
At least one positive inked
margin
Tumour size 0.018
3.5 (1.2–9.7)
– 0.005
2.8 (1.4–6)
0.005
3 (1.4–6.3)
0.051
2.2 (1–5)
T stage 0.029
9.7 (1.2–74)
– 0.003
4 (1.6–10)
0.018
2.94 (1.2–7)
0.007
3.6 (1.4–9)
N stage 0.018
4.5 (1.3–16)
0.009
3.2 (1.3–7.7)
0.004
3.2 (1.4–7)
0.005
3 (1.4–7)
–
LNR>0.2 – 0.017
2.5 (1.2–5.2)
0.040
2.4 (1–5.6)
– –
PV-SMVR <0.001
5 (2.2–12)
0.012
2.7 (1.2–6)
– – –
Posterior margin N-stage – – 0.012
3.45 (1.3–9)
0.043
2.49 (1–6)
0.035
2.42 (1–5.5)
LNR >0.2 0.075
3.1 (0.9–11)
0.029
2.5 (1.1–5.6)
0.005
2.9 (1.4–6)
0.015
2.5 (1.2–5.2)
0.022
2.4 (1.1–5)
PV-SMVR 0.007
6.0 (1.7–22)
– – – –
Neoadjuvant treatment – – 0.045
0.4 (0.1–1)
– 0.077
0.464 (0.2–1.1)
PV-SMVm Tumour size 0.053
3.1 (1.0–9.6)
– 0.001
3.7 (1.6–8.4)
0.001
3.9 (1.7–8.8)
0.002
3.2 (1.5–6.7)
T-stage – 0.049
4.5 (1.0–20)
0.007
4.8 (1.5–15)
0.016
3.6 (1.3–10)
–
N-stage – 0.042
3.2 (1.0–9.8)
0.032
2.5 (1.1–5.9)
0.026
2.6 (1.1–6)
–
PV-SMVR <0.001
5.6 (2.3–14)
0.011
2.9 (1.3–6.5)
0.012
2.7 (1.2–5.8)
0.016
2.6 (1.2–5.6)
–
SMAm Tumour size – – 0.023
3.0 (1.16–8.06)
0.009
3.6 (1.4–9.3)
<0.001
5.4 (2.2–13)
N-stage – – – 0.038
2.99 (1.06–8.39)
–
LNR >0.2 0.010
4.3 (1.4–13)
0.014
3.6 (1.3–9.9)
0.004
3.2 (1.4–7)
0.013
2.7 (1.2–5.8)
–
Grade 3 0.050
3.6 (0.8–16)
0.002
4.39 (1–19)
0.014
4.83 (1.5–16)
0.008
5.7 (1.74–18.8)
0.002
8.00 (2.44–26.2)
PV-SMVR 0.002
5.8 (1.9–18)
0.011
3.8 (1.4–11)
– – –
Male versus female – 0.024
0.2 (0.04–0.8)
0.054
0.4 (0.2–1.0)
– –
Vascular margin
PV-SMVm + SMAm
Tumour size 0.009
4.4 (1.4–14)
0.027
2.7 (1.1–6.4)
<0.001
4.47 (2.0–9.8)
<0.001
4.7 (2.1–10)
<0.001
4.2 (1.9–8.9)
T-stage 0.033
9.2 (1.2–71)
0.042
3.7 (1.0–13)
0.002
5.3 (1.8–15)
0.005
4.2 (1.5–11)
0.009
3.4 (1.3–8.4)
N-stage 0.022
4.3 (1.2–15)
0.018
3.4 (1.2–9.6)
0.011
2.9 (1.3–6.6)
0.001
3.0 (1.3–6.8)
0.043
2.2 (1.0–4.9)
LNR >0.2 0.016
2.56 (1.2–5.5)
0.015
2.6 (1.2–5.6)
0.020
2.5 (1.1–5.3)
0.043
2.4 (1.0–5.4)
Grade 3 0.049
4.0 (1.3–12)
0.067
3.6 (1.1–11)
PV-SMVR <0.001
5.5 (2.4–13)
0.006
3.0 (1.4–6.6)
0.018
2.6 (1.2–6)
0.023
2.5 (1.1–5.7)
0.028
2.7 (1.1–6.4)
Male versus female – – 0.022
0.45 (0.22–0.88)
0.037
0.48 (0.24–0.95)
–
LNR, lymph node ratio; PV-SMVm, portal vein–superior mesenteric vein margin; SMAm, superior mesenteric artery margin (uncinate margin).
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margins,34 were distinguished from the posterior margin. For the
0-mm and 1.0-mm margin definitions, the SMVm was the most
commonly involved (18% and 41%, respectively), as in the study
by Pingpank et al.,8 which contrasts with the particularly low rates
of 3–10% reported by others.21,46 For the 0-mm and 1.0-mm
margin definitions, the SMAm was invaded in 10% and 25% of
specimens, respectively, and the vascular resection margin was
invaded in 23% and 49% of specimens, respectively. In the present
study, no significant difference in R1 rates emerged between the
1.0-mm and 1.5-mm margins. The median and mean clearances
were lower for the PV-SMVm than for the SMAm. The assessment
of resection margins along both vessels gives an accurate picture
of resection margin status because these areas represent the most
critical part of the CRM in terms of the occurrence of microscopic
residual disease. Optimization of this crucial resection margin
using the artery-first approach has been advocated,54 and the issue
of a systematic en bloc PV-SMVR after a first SMA approach was
addressed recently by Turrini et al.55
Table 5 Multivariate analysis of factors associated with at least one positive margin for each of the margins at each width from 0 mm to
2.0 mm. Values in bold refer to factors that reached significance at a P-value of <0.05; values in italics refer to factors that did not reach
significance at a P-value of <0.05, but tended towards significance at a P-value of <0.10
Margin widths, mm
0 0.5 1.0 1.5 2.0 mm
Margins Variables P-value
Odds ratio (95% confidence interval)
At least one positive inked
margin
Tumour stage – – 0.073
2.5 (1.0–6.9)
– 0.039
2.8 (1.0–7.3)
PV-SMVR <0.001
4.7 (2.0–12)
0.016
2.8 (1.2–6.4)
– – –
Posterior margin LNR >0.2 0.036
4.4 (1.10–17.7)
0.053
2.2 (0.989–5.13)
0.059
2.2 (0.968–5.12)
– –
PV-SMVR 0.005
7.5 (1.8–31)
– – – –
PV-SMVm Tumour size – – – 0.066
2.2 (1.0–5.0)
0.055
2.1 (1.0–4.4)
PV-SMVR 0.001
4.5 (1.8–11)
0.035
2.5 (1.0–5.7)
– – –
SMAm Tumour size – – – – 0.020
3.0 (1.2–8.0)
Grade 3 – – 0.049
4.05 (1.1–14)
0.046
4.39 (1.2–16)
0.032
5.5 (1.5–20)
LNR >0.2 0.019
5.8 (1.3–25)
– – – –
PV-SMVR 0.009
6.8 (1.6–28)
0.047
3.9 (1.0–15)
– – –
Vascular margin
PV-SMVm + SMAm
Tumour size – – 0.065
2.2 (0.97–5.1)
0.034
2.5 (1.0–5.7)
0.017
2.6 (1.2–5.6)
LNR >0.2 – 0.065
2.3 (0.95–5.5)
– – 0.099
2.17 (0.86–5.47)
PV-SMVR <0.001
5.2 (2.0–13)
0.012
3.06 (1.3–7.4)
– – 0.080
2.31 (0.91–5.88)
aVascular margin: SMAm + PV-SMVm.
PV-SMVR, portal vein–superior mesenteric vein resection; LNR, lymph node ratio; PV-SMVm, portal vein–superior mesenteric vein margin; SMAm,
superior mesenteric artery margin (uncinate margin).
Figure 4 Overall survival in 139 patients for whom data were avail-
able at the time of the study. Hazard ratio: 0.64, 95% confidence
interval 0.37–1.11; P = 0.106
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In the present study, the anterior surface of the specimen (ante-
rior part of the whole CRM) was not inked. Assessment of the
anterior resection margin as a part of the CRMwas recommended
several years ago in Japan,56 and subsequently in Europe27 and
more recently in North America.40,43 Invasion of the anterior
surface has been reported as marking a margin relevant to the
definition of ‘radicality’ in the Japanese pancreatic cancer regis-
try.57 However, the anterior/serosal margin has not been consid-
ered as a transection margin.28,34,46 Invasion has been reported in
7–15% of patients,26–28 but isolated infiltration of the anterior
surface is unusual28 and has sometimes not been considered as
indicating R1 resection.30 It was therefore proposed that assess-
ment of this margin should be excluded from a standardized
pathological protocol,28 or that the 0-mm clearance rule should be
used.27,29 In the current study, despite the lack of inking of the
anterior surface of the specimen, nearly 70% of patients were
found to have at least one positive margin according to the
1.00-mm clearance rule, which is closest to the rates reported in
recent series using a standardized pathological protocol.26,28,30–32,34
In the present study, the fact that 19% of patients had received
neoadjuvant treatment, including irradiation in nearly 60%, may
have biased the evaluation of resection margins. Low rates of R1
resection are usually observed after neoadjuvant radiochemo-
therapy, especially for the SMAm8,22,58,59 and SMVm.8 However,
neoadjuvant therapy has been reported as a non-significant pre-
dictor of SMAm status.22,58 In the present study, neoadjuvant treat-
ment was correlated with a reduced risk for a positive posterior
margin at only the 1.0-mm definition in univariate analysis.
What constitutes an adequate margin in PDAC resection speci-
mens was recently discussed by Verbeke et al.60 Indeed, the
1.0-mm margin rule42 has been extrapolated from the circumfer-
ential margin recognized as discriminant of recurrence in rectal
cancer, but has never been validated for PDAC. Its relevance is
questionable because of the infiltrative, dispersed and discontinu-
ous growth pattern of PDAC.24,60 Chang et al. reported that a
minimum clearance of 1.5 mm was an independent predictor of
survival in multivariate analysis.46 A revision of the current 0-mm
and 1.0-mm definitions of R1 resection should be considered for
PDAC, as for rectal cancer.32,60,61
Curative resection (R0) is one of the key factors influencing
survival after PD for PDAC.3,5–7,9,15 However, as in the present
study, positive margins are often correlated with other strong
pathologically prognostic factors that may be potential confound-
ing variables in an assessment of the correlation of a positive
resection margin with local recurrence and survival.
Numerous published multivariate analyses have emphasized
the prognostic value of tumour size,7,10,22,34,46 tumour stage,34 grade
3,7,10,15,34,62,63 lymph node involvement,10,16,21,46 LNR15,64,65 and vas-
cular invasion.46 Regardless of pre- or postoperative treatment,
other clinical and biological variables have been reported as prog-
nostic factors, including preoperative variables such as insulin-
dependent diabetes and a CA 19-9 level of 400 U/ml,15 surgical
variables such as blood loss7,22,53 and postoperative complica-
tions,11,63 and postoperative variables such as persistently elevated
levels of CA 19-9.66 In the present study, patients with a PV-SMVR
had more negative histological factors, including more positive
margins, although they had more often received neoadjuvant
treatment. An increased frequency of positive resection margins
has been reported in patients who required PV-SMVR.21,58 As in
the present study, a recent report by Gnerlich et al. showed that the
invasion of at least one margin was significantly more frequent
(34% versus 22%), and the PV-SMVm was more often invaded
(52% versus 24%) in patients who required PV-SMVR.21
However, Tseng et al. reported that the significantly increased risk
for a microscopically positive SMAm in patients who required
PV-SMVR was associated with tumour size and not with vascular
resection.58
Thus, the effect of positive resection margins per se remains
controversial,25 and some authors consider the finding of a posi-
tive margin to represent a function of tumour size and anatomical
location,22 rather than a surrogate marker of tumour biology.5,16,46
The suggestion that positive margins may be predictive of the
risk for local recurrence makes sense.13,20,21,28,53 The rate of local
recurrence after resection of PDAC based on autopsy findings67
seems to be at odds with the R1 rate reported in series using a
standardized pathological protocol for the examination of PD
specimens.27 However, the rate of isolated local recurrence is
usually below 25%, and in clinical practice, the majority of
patients hadmetastases at the time of diagnosis of local recurrence
and died of metastases.13,21 In the present study, in which
follow-up was relatively short, 16 of 31 instances of local recur-
rence were isolated and, as previously reported, resection margin
status did not affect the pattern of first recurrence.58
Microscopic resection margin involvement (R1) has been
reported as an independent predictor of poor longterm survival
following PD for PDAC in several studies,5–21,63 but R1 status was
Figure 5 Progression-free survival in 139 patients for whom data
were available at the time of the study. Cases of postoperative
mortality were excluded (n = 5). Numbers of events were, respec-
tively, 57 in the R0 group and 27 in the R1 group. Patients in whom
an R0 resection was achieved had a significantly better outcome
than those in whom an R1 resection was performed (at least one
positive margin according to the 0-mm definition). Hazard ratio:
0.59, 95% confidence interval 0.37–0.94; P = 0.023
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not identified as a significant factor for survival in a meta-analysis
of data collected from randomized controlled trials (RCTs) of
adjuvant treatment.23 In some studies, R1 resection was found to
correlate with poorer survival on univariate but not multivariate
analysis.26,30 In other studies, as in the present study, median OS
did not differ significantly, whereas survival time of patients with
R0 resections varied by 6 months,22,28 which may be considered
a substantial difference in PDAC. The ‘vascular’ margins (medial
part of the CRM) seem to be the most important.8,21,26,28,31,34 As
Jamieson et al. have reported, the involvement of ‘transection’
margins was an independent predictor of poor outcome even in
patients with node-negative disease; by contrast, outcomes in
patients with posterior margin and anterior surface involvement
(‘mobilization’ margins) were similar to those in patients with R0
resections.34 In the present study, the median and 2-year PFS were
significantly worse in patients with at least one 0-mm positive
margin; positive vascular margins significantly decreased PFS, but
a positive posterior margin had no impact. Pingpank et al.
reported a significant decrease in disease-free survival in patients
with SMVm and SMAm involvement, but not in those with pos-
terior margin or pancreatic margin involvement.8 Furthermore,
multiple margin involvement, which has been reported in 20–45%
of PD specimens,21,26,28,30,34,68 significantly increased the risk for
local recurrence21 and was correlated with a significantly worse
outcome.34,68 In the current study, the impacts of R1 status
(defined as a 0-mm invasion of at least one margin) on PFS and
OS estimated by the Cox model are close (HR = 0.59 and 0.64,
respectively): this suggests that the non-significance of the impact
of R1 status on OS is related to the lack of power of the study
(resulting from an insufficient number of observed deaths).
Adjuvant chemotherapy is currently the standard treatment for
patients following a potentially curative PD for PDAC in
Europe.5,6,35 It is noteworthy that the R1 rates in RCTs that have led
to changes in clinical practice were very low (19% in ESPAC-15
and 17% in CONKO-0016). Two recent meta-analyses and a large,
prospective monocentre database have suggested that in patients
with R1 status, postoperative radiochemotherapy may be useful
and probably better than chemotherapy alone.23,63,69 Thus, post-
operative radiotherapy may be considered if radiotherapy has not
been administered before the intervention. Neoadjuvant treat-
ment is promising70 and may decrease the rate of microscopically
positive resection margins and the rate of local recurrence.22,58,59
However, there is currently a lack of randomized trials showing
that neoadjuvant treatment abrogates the adverse effect of R1
status and results in a significant increase in disease-free or overall
survival.8,59 In any case, the use of a standardized pathological
protocol for the stratification of patients in clinical trials of adju-
vant treatment is relevant today.37
Conclusions
The present prospective study shows that recently reported results
of positive margins are reproducible in a multicentre trial and that
rates obviously depend on the definitions of microscopic invasion
used. Achieving better understanding of the biology of pancreatic
cancer will undoubtedly represent the most important step
towards improving survival. Meanwhile, the standardization of
histological examination is not only necessary to provide accurate
prognostic information, but may represent a significant step
forward in the design of future RCTs and the optimization of
adjuvant treatment strategies.
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Appendix
Correspondence between terms used to define resection margins in pancreatoduodenectomy
specimens according to the Royal College of Pathologists (RCPath) (UK) (http://www.rcpath.org)
and the College of American Pathologists (CAP) (http://www.cap.org/)a
Terminology RCPath,42
Verbeke et al.26
AJCC, CAP38,39 Jamieson et al.34
CRM Anterior, medial and posterior RMs Transection versus mobilization margins
SMAm SMAm + Pm = posterior CRM Mesenteric or uncinatec Transection
SMVm Medial part of the CRMb Transection
Vascular margind SMAm + SMVm Medial transection margin
Pm Part of the posterior CRM Deep radial posterior margin Posterior mobilization
Anterior surface Anterior CRM Anterior mobilization
aIn the present study, the superior mesenteric artery margin (SMAm) and the mesenterico–portal vein groove or superior mesenteric vein margin (SMVm)
were assessed separately.
bSurface of the pancreatic head that faces the SMV and separates the anterior from the posterior CRM.28
cThe soft tissue adjacent to the right lateral border of the proximal 3–4 cm of the SMA. The term ‘retroperitoneal margin’, commonly used in place of SMAm
or uncinate margin, should be abandoned.
dIn the present study, the SMAm and SMVm were assessed separately; they both define the vascular margin (or medial transection margin34 of the
mesopancreas31,34).
The section of the pancreatic neck, which is not included in this table, is a transection margin.
AJCC, American Joint Committee on Cancer; RM, resection margin; CRM, circumferential resection margin; SMAm, superior mesenteric artery margin;
SMVm, superior mesenteric vein margin (or mesenterico–portal vein groove); Pm, posterior margin.
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